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Background: The role of cell-free DNA (cfDNA) in the pathogenesis of inflammatory
bowel disease (IBD) has been recently suggested. The aim of this study was to
analyze circulating cfDNA and deoxyribonuclease (DNase) activity in IBD patients in
clinical remission.
Materials and Methods: Plasma and serum were obtained from 72 patients with
Crohn’s disease and 28 patients with ulcerative colitis. Total cfDNA, nuclear DNA
(ncDNA), mitochondrial DNA (mtDNA) and DNase activity were measured.
Results: IBD patients showed higher levels of both ncDNA and mtDNA compared to
healthy controls. Concentration of ncDNA was higher in males compared to females,
including patients and healthy controls. However, unlike males higher amount of ncDNA
was found in female IBD patients compared to healthy controls. DNase activity was
significantly lower in male IBD patients compared with healthy controls. In addition, there
was a negative correlation between DNase activity and ncDNA levels inmale IBD patients.
Conclusions: Herein we present increased amount of circulating ncDNA and mtDNA
in IBD patients in clinical remission. Thus, unlike total cfDNA, circulating ncDNA and
mtDNA might not represent the optimal biomarkers of disease activity. This is also the
first report on sex difference in circulating ncDNA levels, possibly associated with lower
DNase activity in males.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a group of multifactorial, autoimmune disorders with
multifactorial etiology, which includes Crohn’s disease (CD) and ulcerative colitis (UC). Despite
extensive research, the detailed pathogenesis has not been sufficiently explained yet. Current
therapy is mostly based on ameliorating inflammatory processes, which does not cover the whole
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complexity of the disease and inevitably leaves a large group
of patients without efficient therapy. Apart from microbiome-
directed studies, novel approaches to uncover the pathogenesis
of IBD include the analysis of cell-free (or extracellular)
nucleic acids.
Increased concentrations of circulating cell-free DNA
(cfDNA) has been previously shown to be associated with
multiple inflammatory disorder, including sepsis or hepatorenal
injury (1, 2). A number of studies have suggested a role of cfDNA
in IBD. The role of cell-free nucleic acids and their clinical
relevance in IBD has been recently reviewed by Kubiritova
et al. (3). To this date, a number of animal studies have
proved the role of cfDNA in IBD. CfDNA is able to bind to
toll-like receptor 9 (TLR9) and activate the pathway leading
to inflammatory responses. This designates cfDNA a potential
marker of inflammation. However, several experiments on
mice have paradoxically confirmed the protective role of
these pathways in IBD (4, 5). On the other hand, activation
of TLR9 significantly exacerbated mouse colitis in a different
study (6). In addition, a positive correlation between plasma
cfDNA concentration and severity of colitis has been shown (7).
Interestingly, concentrations of circulating cfDNA negatively
correlated with deoxyribonuclease (DNase) activity in the colon
tissue (8).
The above mentioned findings, however, have been so far
confirmed only in a few patient studies. Circulating total cfDNA
concentrations in UC patients were significantly positively
correlated with the clinical severity of UC (7). Increased levels
of circulating cfDNA of mitochondrial origin (mtDNA) were
observed in a variety of inflammatory diseases and acute injuries
(9–11). However, there is only one study showing increased levels
of circulating mtDNA in active IBD patients. MtDNA levels
significantly correlated with disease markers and activity (12). In
addition, a reduced serum DNase I activity was also observed in
patients with IBD (13). Thus, the nature of circulating cfDNA in
IBD patients has not been extensively studied yet. The aim of this
study was to analyze the concentrations of circulating cfDNA and
the activity of DNase in IBD patients in clinical remission and
look for potential sex differences.
MATERIALS AND METHODS
Patients and Controls
One hundred IBD patients were recruited from outpatient setting
from the Gastrointestinal Unit of the 5th Department of Internal
Medicine, University Hospital Bratislava between September
2016 to June 2017. Diagnosis of CD and UC was made upon
endoscopic, histologic and clinical findings according to standard
clinical, endoscopic and histological criteria. At the time of
sampling, all CD patients had the Crohn’s Disease Activity
Index score equal or below 150 and Harvey-Bradshaw index
score below 5. Patients with UC had the Partial Mayo Score
below 2. All patients were on ongoing treatment that included
one or more of the following drugs: infliximab, vedolizumab,
ustekinumab, adalimumab, azathioprine, mesalazine. Five CD
patients and 4 UC patients were current smokers. Twenty-nine
healthy non-smokers with no history of IBD and no acute or
chronic illness were recruited as non-IBD controls. Informed
TABLE 1 | Characteristics of the study groups.
Controls CD UC
n 29 72 28
Age 27 (18–46) 41 (22–69) 40 (21–71)
Females % 59 39 50
BMI 22.6 24.3 24
CDAI – ≤150 –
HBI – <5 –
pMayo – – <2
CD, Crohn’s disease; UC, ulcerative colitis; BMI, body mass index; CDAI, Crohn’s disease
activity index; HBI, Harvey-Bradshaw index; pMayo, partial Mayo score.
consent was obtained from all participants prior to their inclusion
in the study. Characteristics of patients and healthy controls
are listed in Table 1. The study has been approved by the local
ethics committee and has been performed in accordance with the
ethical standards laid down in the 1964 Declaration of Helsinki
and its later amendments.
Blood Samples Processing
Samples were taken from IBD patients during their outpatient
visit. Healthy volunteers provided their blood samples at the
Faculty of Medicine, Comenius University, Bratislava. Venous
blood was taken into EDTA and serum Vacuette tubes (Greiner
Bio-One, Frickenhausen, Germany) and processed within 2 h.
Samples were centrifuged at 1,600 g for 10min at 4◦C, the
supernatant was transferred into a new 15-mL tube and
centrifuged again at 16,000 g for 10min at 4◦C. The resulting
supernatant was used as cell-free plasma and serum, respectively.
Extraction and Measurement of cfDNA
DNA was extracted from 200 µL cell-free plasma samples using
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. The concentration of
total cfDNA was measured using Qubit Fluorometer and Qubit
dsDNA HS Assay Kit (Invitrogen, Los Angeles, California, USA)
and expressed as ng of DNA per mL of plasma.
Quantitative PCR
Quantitative PCR was used for the quantification of ncDNA
and mtDNA in cfDNA extracted from plasma of both sets.
Quantitative PCR was performed on Mastercycler realplex
4 (Eppendorf, Hamburg, Germany) using the SsoAdvanced
Universal SYBR Green Supermix (Bio-Rad, Hercules, California,
USA) with the following program: 1 cycle of 2min at 95◦C,
followed by 45 cycles of 95◦C for 15 s for denaturation and 60◦C
for 1min for annealing. After completion of all cycles a melting
curve was obtained. Primers were designed for the amplification
of part of human beta globin gene to quantify ncDNA (F: GCT
TCT GAC ACA ACT GTG TTC ACT AGC, R: CAC CAA CTT
CAT CCA CGT TCA CC) and part of human cytochrome c
oxidase gene to quantify mtDNA (F: CAT AAA AAC CCA ATC
CAC ATC A, R: GAG GGG TGG CTT TGG AGT). The amount
of ncDNA and mtDNA was expressed as number of copies per
mL of plasma.
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DNase Activity
DNase activity in plasma samples was measured by single radial
enzyme diffusion method using 1% agarose gel (20mM Tris–
HCl, pH 7.5, 2mMMgCl2, 2mM CaCl2), which contained DNA
isolated from chicken liver (7ml of 5 mg/ml DNA in 100ml
of gel). From each serum sample 1 µl was pipetted into the
gel and incubated over night at 37◦C in the dark. Dilutions of
DNase I (Qiagen, Hilden, Germany) of known concentrations
were used for creating the calibration curve. The diameters of
circles were measured by ImageJ software (Madison, Wisconsin,
FIGURE 1 | Concentration of total cfDNA, ncDNA and mtDNA in IBD patients and controls. No difference in total cfDNA between healthy controls and patients was
found (A,B). IBD patients showed higher levels of both ncDNA and mtDNA compared to healthy controls (C: p = 0.0061 and E: p = 0.0387). The difference was also
seen in both subgroups of CD and UC patients (D: p = 0.0062 for CD and 0.0105 for UC against control and F: p = 0.0345 for CD and p = 0.0365 for UC against
control). *P < 0.05, **P < 0.01.
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FIGURE 2 | Sex differences in cfDNA, ncDNA and mtDNA. Higher total cfDNA
was found in male IBD patients compared with female patients (p = 0.0478);
however, this difference was not found in the subgroups of CD and UC (A).
Concentration of ncDNA is higher in males compared to females in healthy
controls (p = 0.0274), IBD patients (p = 0.0345) and CD subgroup (p =
0.0309) (B). No sex difference was found in mtDNA in any of the groups (C).
*P < 0.05.
USA). DNase activity was expressed as Kunitz units (KU) per mL
of plasma.
Statistical Analysis
All data were analyzed and presented using GraphPad Prism
6.0 (GraphPad Software, La Jolla, California, USA) software
using unpaired t-test and one-way ANOVA with Tukey’s post
hoc test, where appropriate. P-values of <0.05 were considered
significant. All data are presented as mean± SD.
RESULTS
Increased Circulating ncDNA and mtDNA
in IBD Patients
When the subject groups were analyzed regardless of sex, the
difference between healthy controls and patients was not present
in total cfDNA (Figures 1A,B). However, IBD patients showed
higher levels of both ncDNA and mtDNA compared to healthy
controls (Figures 1C,E). This difference was seen in both CD and
UC patients (Figures 1D,F).
Sex Difference in Circulating ncDNA
Although no sex difference was found in total cfDNA and
mtDNA levels in any of the groups (Figures 2A,C; except
for cfDNA in all IBD), absolute concentration of ncDNA is
significantly higher in males compared to females (Figure 2B).
This is true for CD patients as well as IBD as a whole. In UC
patients, the difference is not significant, likely due to lower
number of subjects. This sex difference is also obvious in healthy
controls with males showing higher levels of ncDNA.
Increased Circulating ncDNA and mtDNA
in Female IBD Patients
In females, no difference was found between groups in total
cfDNA (Figure 3A); on the other hand, a significantly higher
amount of circulating ncDNA was found in female IBD patients
(both CD and UC) compared to healthy controls (Figure 3B).
Although not significant, this finding was seen in mtDNA as
well (Figure 3C). In males, no significant differences between
groups were shown, although the trend toward higher ncDNA
and mtDNA in IBD patients compared with healthy controls can
be seen (Figures 4A–C).
Lower DNase Activity in Male IBD Patients
In females, no difference was found between groups in
DNase activity (Figure 5A). Interestingly, DNase activity was
significantly lower in male IBD patients (both CD and UC)
compared with healthy controls. In addition, there is a significant
negative correlation between DNase activity and ncDNA in
male IBD patients (Figure 5B). However, no correlation was
found between DNase activity and any form of DNA in female
IBD patients.
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FIGURE 3 | Total cfDNA, ncDNA and mtDNA in females. No difference was
found between groups in total cfDNA (A). Higher amount of ncDNA was found
in female IBD patients (p = 0.0098), including both CD (p = 0.0108) and UC (p
= 0.0110) compared to healthy controls (B). Similar trend is seen in mtDNA,
although the differences were not significant (C). *P < 0.05, **P < 0.01.
FIGURE 4 | Total cfDNA, ncDNA and mtDNA in males. No significant
differences between groups were shown in cfDNA (A), although a clear trend
toward higher ncDNA and mtDNA in IBD patients compared with healthy
controls can be seen (B,C).
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FIGURE 5 | DNase activity in healthy controls and patients. In females, no difference was found between groups. DNase activity was lower in male IBD patients
(p = 0.0001), including both CD (p = 0.0002) and UC (p = 0.0497) compared with healthy controls (A). Negative correlation was found between DNase activity and
concentration of ncDNA in male IBD patients (p = 0.0198) (B). *P < 0.05, ***P < 0.001.
DISCUSSION
Our study is the first one analyzing the amount of circulating
total cfDNA, ncDNA and mtDNA in human IBD patients in
clinical remission. It was previously found that total circulating
cfDNA, as well as mtDNA is increased in active IBD patients
(7, 12). This clearly shows the potential of these molecules
to serve as biomarkers of disease severity and potentially as
therapeutic targets.
It has been shown that circulatingmtDNA can activate various
inflammatory responses via TLR9 receptors, including NLRP3
inflammasomes and neutrophils (14, 15). Boyapati et al. proved
that deletion of the Tlr9 gene results in the attenuation of acute
colitis in mice, which indicates that mtDNA-TLR9 signaling
represents a targetable pathway in IBD (12). Herein we present
that the amount of circulating ncDNA and mtDNA is also
increased in non-active IBD patients in clinical remission. Thus,
unlike total cfDNA, circulating ncDNA and mtDNA might not
represent the best biomarkers of disease activity, since their
amounts are higher even in IBD patients in clinical remission
compared with healthy controls.
Although absolute concentration of ncDNA was higher in
males than females, the difference between healthy controls and
IBD patients is only significant in females. This is mainly because
healthy male controls had values which are higher compared
with healthy female controls and, in fact, are close to male IBD
patients. Thus, circulating ncDNA amount clearly differentiates
between non-IBD and IBD individuals, but only in females. This
might be due to the fact that circulating levels of neutrophil
extracellular traps (NETs) are higher in males compared with
females (16). NETs represent one of the sources of ncDNA.
NcDNA is a potentially pro-inflammatory molecule playing role
in initiating and sustaining the innate immune response (17).
This is the first study that shows the sex difference in circulating
ncDNA levels in IBD patients. Our findings are in accordance
with a study byMeddeb et al. that has shown higher ncDNA levels
in males compared to females and no sex difference in mtDNA in
healthy individuals (18).
One of the possible limitations of this study is the age
difference between healthy control group and IBD patients
(mean age: 27 for controls, 41 for CD, 40 for UC). Age was
previously found to be a significant factor influencing the
levels of ncDNA, but not mtDNA in healthy individuals (18).
Nevertheless, no significant correlation was found between age
and cfDNA, ncDNA or mtDNA concentrations in any of the
subject populations in this study, even if sex was considered
(data not shown). Another limitation of our current study is the
fact that only IBD patients in clinical remission were enrolled.
However, data from the literature provide some insight into
the nature of cfDNA in active IBD patients. Our study focused
only on patients in clinical remission. Future studies should
include patients with various disease activity scores and long-
term sampling of the same patients to monitor the dynamics of
the cfDNA in active and non-active stages of the disease.
The group ofMonteleone has shown that NETs, which include
both ncDNA and mtDNA, increased in colon mucosa and
sustain inflammatory processes in UC (17). On the other hand,
circulating gut-derived cfDNA has not proved higher in IBD
patients (19). The authors did not find intestinal cfDNA in
plasma of healthy individuals. In addition, active IBD patients
only had minimal amounts of circulating intestinal cfDNA,
which were not significantly different from healthy controls. This
finding indicates that circulating total cfDNA is likely not of
intestinal origin, although additional studies are lacking. Our
group has recently shown that total cfDNA increased with the
stage of colitis and mtDNA and ncDNA was not significantly
different compared to control mice (20).
It has been reported that DNase I deficiency promotes
susceptibility to autoimmune disorders (21). In addition, a
decreased DNase I activity has been previously observed in
active IBD patients (13). Herein we present that this finding
is also valid for IBD patients in clinical remission; however,
this is only true for male patients. Sex difference in serum
DNase activity of IBD patients has not been reported before. We
also reported a significant negative correlation between DNase
activity and circulating ncDNA in male IBD patients, suggesting
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a potential key role of this finding in the pathogenesis of male
IBD. Injection of DNase was effective in experimental treatment
of sepsis (1) and hepatorenal injury (2). However, no significant
therapeutic effect of intravenous DNase I injection was proved
in mouse colitis, possibly due to rapid half-life of the enzyme
in the circulation (22). The current study also contributes to the
knowledge on the mechanisms of DNase action from the view of
sex differences.
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